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We analysed 3872 common genetic variants across the ESR1 locus (encoding estrogen 
receptor–alpha) in 118,816 subjects from three international consortia. We found evidence 
for at least five independent causal variants, each associated with different phenotype sets, 
including positive and negative estrogen receptor (ER+/ER-) and human ERBB2 
(HER2+/HER2-) tumor subtypes, mammographic density and tumor grade. The best 
candidate causal variants for ER- tumors lie in four separate enhancer elements and their 
risk alleles reduce expression of ESR1, RMND1 and CCDC170, while the risk alleles of the 
strongest candidates for the remaining independent causal variant disrupt a silencer element 
and putatively increase ESR1 and RMND1 expression. 
 
Single nucleotide polymorphisms (SNPs) at 6q25.1 have been reported to be associated with breast 
cancer susceptibility in genome-wide association studies in women of Chinese1 and European 
ancestry2. Subsequent analyses have demonstrated that SNPs in the same region are associated with 
breast cancer risk for BRCA1 mutation carriers3 and mammographic density4, a strong breast cancer 
risk factor. To date, however, attempts to identify the candidate causal variant(s) underlying the 
associations have been inconclusive3,5,6. Here, we report the fine- scale mapping and 
comprehensive analysis of the genotype-phenotype associations in this region, using dense 
genotyping and imputed data from the custom-designed iCOGS (Collaborative Oncology Gene-
environment Study) array, in 118,816 subjects from three consortia: the Breast Cancer Association 
Consortium (BCAC), the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and 
the Markers of Density Consortium (MODE). We additionally demonstrate, through functional 
analyses, the likely modes of action of the strongest candidate causal variants. 
 
 
RESULTS 
Genetic epidemiological studies 
902 SNPs across a 1 Mb region containing ESR1 were successfully genotyped in 50 case- control 
studies from populations of European (89,050 participants) and Asian ancestry (12,893 
participants) within BCAC, together with 15,252 BRCA1 mutation carriers within CIMBA. 
Mammographic density measures were available for 6,979 women from the BCAC studies and an 
additional 1,621 women from the MODE consortium, who had also been genotyped using the 
iCOGS array. Subsequently, genotypes of additional variants with minor allele frequency > 2% 
were imputed in all European ancestry participants, using data from the 1000 Genomes Project as a 
reference. In total, data from 3,872 genotyped or imputed (imputation info score > 0.3) SNPs were 
analysed. Results for all SNPs associated with overall breast cancer risk (P < 10-4) are presented in 
Supplementary Table 1. Manhattan plots of the associations of these 3,872 SNPs with the main 
phenotypes are shown in Fig. 1. 
 
Conditional analyses 
All genotyped and imputed SNPs displaying evidence for association with overall breast cancer 
risk in women of European ancestry (P < 10-4) were initially included in forward stepwise logistic 
regression models for ER- and ER+ breast tumor risk. The most parsimonious models (see Online 
Methods) included four SNPs for ER- and four for ER+ breast cancer, with three being common 
to both models. In each model, all selected SNPs fell into a subset of five bins of correlated SNPs 
(r2
 
> 0.8). Stepwise regression models were independently fitted to breast cancer risk in the 
CIMBA BRCA1 mutation carriers and to mammographic density (measured as mammographic 
dense area (DA) - see online Methods for full details). For the BRCA1 mutation carriers and for 
mammographic DA, the SNPs in the best-fitting models also fell within a subset of the originally 
defined five bins. For further analyses, we selected the directly genotyped SNP that was most 
significantly associated with the predominant phenotype for that bin. Regression analyses were 
repeated using just these five SNPs, with each representing an independent signal7. Results are 
presented in Table 1. Additionally, in the BCAC studies we were able to examine SNP 
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associations with risks of HER2+, HER2- and progesterone receptor (PR+ and PR-) tumor 
subtypes and with tumor grade at diagnosis. 
 
There were weak but detectable correlations between the representative SNPs of signals 1, 2, 3 and 
4 (Table 1 and Supplementary Table 2). We therefore modelled the associations with each SNP 
conditional on the other four; these conditional risk estimates and significance levels are also 
presented in Table 1. At conditional significance levels of P < 10-3 four of the lead SNPs (1, 2, 4 
and 5) were independently associated with risk of developing ER- breast cancer (Table 1). 
Another, partially overlapping, set of four (1, 2, 3 and 5) was associated with ER+ tumor risk 
(Table 2 and Supplementary Table 3), while another sub-set (1, 2, 3 and 4) was associated with 
breast cancer risk in BRCA1 mutation carriers (Table 1). The per-allele ORs were higher for ER- 
than ER+ disease for three lead SNPs (signals 1, 2 and 5), while signal 3 representative SNPs 
displayed smaller effects of similar magnitude on ER- and ER+ tumor risks. Mammographic DA 
was associated with signal 2 and less strongly with signal 1 representative SNPs (Table 1). We 
additionally carried out a meta-analysis of the SNP associations with breast cancer risk for 
CIMBA BRCA1 mutation-carriers and for BCAC ER- tumor risk. We anticipated this analysis 
would increase statistical power to detect ER- risk signals and, indeed, it did strengthen the 
evidence for association of SNP representing signals 1-4 but not for signal 5, which showed no 
association with breast cancer risk in BRCA1 mutation carriers (Table 1). 
 
Tumor subtype and grade analyses 
We next explored the associations of each signal with specific tumor subtype combinations and 
with tumor grade (Fig. 1f, Table 2 and Supplementary Tables 3, 4 and 5). The representative 
SNPs at two signals (3 and 5) were strongly associated with high-grade disease, after adjusting 
for ER-status (p<10-3; Table 2 (bottom line) and Supplementary Table 5). Among ER- tumors, 
three signals (1, 2 and 4) were associated with triple negative (ER-/PR-/HER2-) and high-grade 
tumors, and the rarer (ER-/PR-/HER2+) subtype, with similar ORs (Table 2; Supplementary 
Tables 3 and 5). However, signal 5 was more strongly associated with ER-/PR-/HER2+ disease 
(OR = 1.24; 95% CI 1.12-1.37; P = 2.4x10-5; Table 2), than with triple negative subtype (OR = 
1.08; 95% CI 1.01-1.15; P = 0.016; Table 2, case-only P = 0.021, Supplementary Table 5), 
consistent with the lack of association for breast cancer in BRCA1 mutation carriers, in which 
tumors are predominantly triple negative8. 
 
Haplotype analysis 
We next explored the combined effects of the same five signal–representative genotyped SNPs 
(Supplementary Table 6). Haplotype-specific effects were consistent with additive effects of 
the individual signal-representative SNPs. In particular, haplotype 22221 (all minor alleles except 
for signal 5; frequency 0.005) was associated with the largest increased risks of both ER+ (OR = 
1.38; 95% CI 1.11-1.71; P = 3.3×10-3) and ER- (OR = 2.34; 95% CI 1.76-3.10; P = 3.5×10-9) 
tumors; this group includes the triple negative tumor subtype (detected via the meta-analysis of 
BCAC ER- and CIMBA BRCA1 mutation carriers; P = 8×10-10). Haplotype 22111 (frequency 
0.02) was associated with the highest risk of HER2+ tumors (OR = 1.5; 95% CI 1.21-1.87; P = 
3×10-4) and with mammographic DA (β-coefficient = 0.45; 95% CI 0.20-0.69; P = 3×10-4). 
 
Associations in Asian ancestry studies 
We examined the associations of the five signal-representative SNPs in the nine Asian ancestry 
studies within BCAC (Supplementary Table 7). All five displayed allelic associations in the same 
direction as those in Europeans, with overlapping confidence intervals, consistent with the 
hypothesis that the same candidate causal variants determine risk in both populations. 
 
Determining the candidate SNPs within each signal 
To identify the potential causal variants to be taken forward for functional analysis, we determined 
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the most significant SNP association within each signal and then calculated the likelihood ratio of 
every other SNP relative to that SNP. We assumed that SNPs with a likelihood of < 1:1009 
compared with the most significant SNP for each signal could be excluded from consideration as 
potentially causative variants. Based on the assumption that, within a given signal, the same 
variant(s) would be driving all observed phenotype associations, we derived the list of most likely 
causal SNPs for each. We used the results from one of two analyses to define the list of 
potentially-causal SNPs for each signal: the “BCAC ER-/CIMBA BRCA1 meta-analysis” for 
signals 1, 2 and 4, which were most strongly associated in this analysis, and “overall breast 
cancer risk in BCAC” for signals 3 and 5. These lists of the unexcluded variants are presented in 
Table 3 and are highlighted in Supplementary Table 1.  
 
In signal 1, the most strongly associated variant was rs2046210 (the original Asian GWAS hit1,10) 
with nine other variants (likelihood ratios < 100:1, r2 ≥ 0.89 with rs2046210; spanning positions 
151,935,539-151,954,127) remaining as strong causal candidates. In signal 2, the best causal 
candidate was SNP rs12173570, with two other candidates remaining (likelihood ratios < 100:1, r2 
≥ 0.75 with rs12173570; spanning positions 151,955,914-151,958,815). The European GWAS 
SNP, rs3757318l2, is most strongly correlated with rs12173570 (r2 > 0.45). In signal 3, the best 
causal candidate was rs851984, with three other candidates remaining (likelihood ratios < 100:1, 
r2 = 0.99; spanning two ESR1 introns - positions 152,020,390-152,024,985). In signal 4, the 
top candidate was rs9918437 and two other candidates span another segment of an ESR1 intron - 
positions 152,055,978-152,072,718 (approximately 30 kb telomeric of signal 3, likelihood ratios < 
100:1, r2 > 0.81 with rs9918437). In signal 5, the strongest candidate causal SNP was rs2747652 
(also the signal 5 representative SNP in Table 1) and there were five other candidates (likelihood 
ratios < 100:1; r2 > 0.97; positions 152,432,902-152,440,522) - in the intergenic region between 
ESR1 and SYNE1. Across the five signals, we were able to exclude all but 26 of the original 3872 
variants from being potentially causal. 
 
Local gene expression analyses 
We used four techniques to assess associations between candidate causal variants (or available 
proxy SNPs) in the five signals and local gene expression: (i) ER protein expression, measured by 
immunohistochemistry in normal breast tissue samples from 150 postmenopausal donors, 
identified a significant correlation of the risk-alleles of signal 1 SNPs and reduced ER levels 
(Fig. 2a and Supplementary Figs. 1 and 2). (ii) Comparison of ESR1 expression in breast tumor 
and adjacent normal breast tissue from the METABRIC study by signal-representative SNP 
allele (Fig. 2b and Supplementary Table 8). In patients with ER- tumors, risk-allele-carriers had 
lower median ESR1 expression, in normal tumor-adjacent tissue, than homozygotes for the 
protective allele at signals 1, 4 and 5, though none of the differences were statistically significant. 
By contrast, in patients with ER+ tumors, risk- allele-carriers had higher median ESR1 expression 
in normal tumor-adjacent tissue than homozygotes for the protective allele at signals 1, 3 and 
5. (iii) Allele specific expression (ASE) analysis, using RNAseq data from breast tumor samples 
and SNP array genotype data from The Cancer Genome Atlas (TCGA)11, revealed allelic 
imbalances in ESR1 expression among heterozygotes for proxy SNPs in signals 1, 2 and 3 (Fig. 
2c and Supplementary Table 9). Similar imbalances in CCDC170 expression were detected 
among heterozygotes for signal 2 SNP rs9397437 and in RMND1 expression with signal 3 SNP 
rs851983 (Supplementary Table 9). Such allelic imbalances indicate that risk alleles at these 
signals are associated with expression differences in local genes but they do not indicate the 
directions of association. (iv) Expression quantitative trait locus (eQTL) analysis using the GTEx 
database identified a significant association for SNPs in signal 3 with CCDC170 expression in 
normal breast tissues (Supplementary Table 10). We also performed cis- eQTL analyses on 
the 12 flanking genes in 135 normal breast tissue samples from the METABRIC study, however no 
additional associations were detected (Supplementary Table 11). 
 
	  	  	  	  	   	  	  	  	  	   	  	  	  	  	   12	  	  	  	  
Bioinformatic and chromatin analyses 
Analysis of cis enhancer-gene interactions using PreSTIGE12 showed evidence of multiple 
regulatory elements coinciding with signals 1, 2 and 3 in ER+ MCF7 breast cancer cells (Fig. 3a 
and Supplementary Fig. 3). A “super enhancer”, associated with high levels of H3K27ac histone 
modification, was also identified in MCF7 cells and encompasses the top risk- associated SNPs in 
these three signals (Fig. 3a and Supplementary Figs. 3)13. This super enhancer was most 
readily detectable in MCF7 cells and was not observed in other breast cancer cell lines, normal 
mammary epithelial cells or other tissues analyzed (Supplementary Fig. 4). Chromatin 
conformation capture (3C) experiments revealed that elements within signals 1 and 2 physically 
interacted with the promoters of the ESR1A, ESR1B, RMND1/C6orf211 and CCDC170 in MCF7 
and T47D cells (Fig. 3b and Supplementary Fig. 5a,b). Furthermore, we detected significant 
interactions between signals 3, 4 and 5 and ESR1 and/or RMND1/C6orf211 promoters (Figs. 3c,d 
and Supplementary Figs. 5c,d). The majority of these interactions were restricted to MCF7 and 
T47D (ER+ breast cancer cell lines) but the RMND1/C6orf211 interactions were also detected in 
either Bre-80 or MCF10A (ER- ‘normal’ breast cell lines; Figs. 3b-d and Supplementary Figs. 
5b-d). The most significant 3C-identified interactions for each signal are summarized in 
Supplementary Table 12. 
 
Prioritizing candidate SNPs for functional assays 
We used a combination of in silico and in vitro analyses to prioritise candidate-causal SNPs for 
functional follow-up, utilising previous observations that common cancer susceptibility alleles are 
enriched in cis-regulatory elements and alter transcriptional activity14-16. First, (Table 3) revealed 
that 19/26 top candidates overlapped DNaseI sites and were associated with enhancer-specific 
histone marks such as H3K4me2 and H3K27ac in MCF7 and HMEC breast cells, indicative of 
putative regulatory elements (PREs, Supplementary Fig. 6). We used electromobility shift 
assays (EMSAs) to show that 11/19 SNPs altered the binding affinity of transcription factors 
(TFs) in vitro (Supplementary Fig. 7). Of these, seven fell within promoter-specific long-range 
interactions identified by 3C (Fig. 3 and Supplementary Fig. 5). The seven SNPs prioritized for 
further detailed analyses included 2/10 remaining candidates in signal 1 (rs7763637 and 
rs6557160), 1/3 in signal 2 (rs17081533), 2/4 in signal 3 (rs851982 and rs851983), 1/3 in signal 4 
(rs1361024) and 1/6 in signal 5 (rs910416; Supplementary Table 12). 
 
Luciferase reporter assays 
The regulatory capabilities of the PREs overlapping each signal and the effect of prioritized seven 
candidate SNPs were examined in luciferase reporter assays in ER+ MCF7 and BT474 and ER- 
Bre80 breast cell lines. PRE constructs containing the reference alleles of prioritized SNPs in 
signals 1, 2, 4 and 5 significantly increased their associated target gene promoter activities when 
cloned in either direction, indicating they act as orientation-independent transcriptional 
enhancers. In contrast, a PRE containing the reference alleles of the signal 3 candidates ablated 
target gene promoter activities but only when cloned in the forward direction, suggesting it 
acts as an orientation-dependent silencer (Fig. 4 and Supplementary Figs. 8-10). Notably, 
inclusion of the minor (risk) alleles of individual candidates SNPs in signals 1, 2 and 5 
(rs6557160, rs17081533 and rs910416) significantly reduced ESR1 and RMND1 promoter 
activities, but had no effect on C6orf211 or CCDC170 promoters. However, inclusion of the 
signal 1 haplotype significantly decreased ESR1, RMND1 and CCDC170 promoter activities 
(Fig. 4 and Supplementary Figs. 8 and 9). Inclusion of the individual minor (risk) alleles of 
signal 4 SNP rs1361024 or signal 3 SNP rs851983 in their respective constructs had no 
additional effects. In contrast, inclusion of the signal 3 minor (risk) allele of rs851982 or the 
haplotype construct increased ESR1 promoter activity in ER+ MCF7 and BT474 cells, and 
RMND1 promoter activity in the three cell lines (Fig. 4 and Supplementary Figs. 8, 9 and 
Supplementary Table 12). 
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Transcription factor (TF) binding analyses 
We used both bioinformatic analyses and functional studies to examine DNA-protein interactions 
for the seven prioritised SNPs within each signal. In silico prediction tools including intra-genomic 
replicates (IGR)17, HaploReg18 and Alibaba219 predicted all seven SNPs to alter TF binding 
(Supplementary Fig. 11 and Supplementary Table 13). Competition with known TF binding sites 
suggested the identity of bound proteins for four of the prioritized SNPs including GATA3 
binding to the minor (risk) allele of signal 3 SNP rs851982 and CTCF binding to the minor 
allele of a second signal 3 candidate, rs851983, as well as the common (protective) allele of signal 
4 candidate rs1361024 and c-MYC binding to the common allele of signal 5 candidate rs910416 
(Supplementary Fig. 12 and Supplementary Table 12). Additional well-established breast cell 
TFs, such as ER itself and FOXA1 were also assessed but did not display competitive binding to 
any prioritised SNP sites (Supplementary Fig. 13). Chromatin immunoprecipitation (ChIP) 
confirmed enrichment of GATA3 binding to DNA overlapping signal 3 candidate rs851982, 
but no difference between alleles and CTCF binding to the region overlapping signal 4 
candidate rs1361024 in BT474 cells (Fig. 5a and Supplementary Fig. 14). CTCF also bound to 
the region encompassing signal 3 candidate rs851983 (Fig. 5a and Supplementary Fig. 14 and 
Supplementary Table 12). CTCF mediates long-range chromatin looping, therefore to assess the 
potential impact of signal 4 candidate rs1361024 and signal 3 candidate rs851983 on chromatin 
interactions, allele-specific 3C was performed in heterozygous cell lines. Sequence profiles 
indicated that the protective g-allele of signal 4 candidate rs1361024 increases looping between this 
enhancer and the ESR1 and RMND1 promoters (Fig. 5b and Supplementary Fig. 15a). We found 
no evidence for allele-specific looping between the silencer overlapping signal 3 and local gene 
promoters (Supplementary Fig. 15b). 
 
DISCUSSION 
The fine-scale mapping, bioinformatic and functional analysis presented here provide evidence for 
the existence of at least five, different genetic variants, each with a direct effect on breast cancer 
risk in Europeans; findings also supported by the limited available data in Asian populations. These 
are distributed upstream, within introns, and downstream of ESR1, each in a region, which we 
have demonstrated via reporter assays, is regulatory for ESR1. Some may additionally regulate 
other local genes, RMND1, C6orf211 and CCDC170, previously reported to be co- regulated with 
ESR120. Of note, the four sites more strongly associated with risks of ER- than ER+ tumors (signals 
1, 2, 4 and 5) all overlap enhancer regions and our evidence indicates that the minor (risk) alleles 
of candidate causal variants, within each of these enhancers, act to reduce expression of ESR1, 
RMND1 and CCDC170. In contrast signal 3, which is associated with smaller but equal risks of 
developing both ER- and ER+ tumors, overlaps a gene silencer and the risk alleles of the 
candidate causal variants here increase ESR1 and RMND1 expression. Furthermore, we have 
demonstrated altered binding of looping factor, CTCF, to candidate causal SNPs in signals 3 and 4 
with evidence that the risk allele of signal 4 candidate rs1361024 abrogates binding and reduces 
chromatin looping between this enhancer element and the promoters of ESR1 and RMND1. We 
also provided evidence that signal 5 candidate, rs910416, may display allele-specific binding of c-
MYC. 
 
Notably, the previously unrecognized signal 5 candidates, downstream of ESR1, significantly 
increase the risk of developing the ER-/PR-/HER2+ tumors (a specific-subtype shown to be more 
responsive to the drug trastuzumab) in contrast to the triple negative (ER-/PR-/HER2-) tumor 
subtype, which has already been reported to be associated with other signals at 6q25 as well as with 
19p1321 and 5p15 (TERT)22. We also found evidence that the candidate causal variants at signals 
3 and 5 predispose to aggressive, high-grade breast cancer, independently of ER status. 
 
Mammographic density adjusted for age and BMI, which describes the variation in epithelial and 
stromal tissue on a mammogram, is one of the strongest known risk factors for breast cancer23, 
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and has been shown to have a shared genetic basis with breast cancer, mediated through a large 
number of common variants24. Associations between ESR1 SNPs and mammographic density have 
previously been reported25-27, but in this detailed analysis, only signal 2 was clearly associated with 
mammographic DA (P = 1.7x10-5), although signal 1 also showed some evidence of an effect in the 
conditional analysis (P = 0.017). Although adjusting the breast cancer analysis of signal 2 for 
mammographic DA produced some attenuation of the associated effect, the lead SNP remained 
significantly associated with breast cancer risk (unconditional OR = 1.30 (1.13-1.49) P = 0.00024; 
OR conditional on DA = 1.24 (1.08-1.43) P = 0.0025), suggesting either that the mechanism by 
which the signal 2 candidate causal variant affects breast cancer risk is not mediated through 
mammographic density, or alternatively that DA, as measured here, is unable to capture the 
association with breast composition that is most relevant to risk. This phenomenon, whereby the 
association with risk appears to be partially independent of mammographic density, has also 
been observed for the 10q21.2 breast cancer locus4. 
 
SNPs in the ESR1 region have previously been reported to be associated with bone mineral 
density28,29. These include SNPs within signal 1 (rs6930633, r2 = 0.73 with rs3757322) and 
signal 3 (rs2982575, r2 = 0.57 with rs851984), although the SNP with most significant reported 
association with bone density measures, rs4870044, was not associated with breast cancer risk (P > 
10-4) in our analysis, nor correlated with any signal-representative SNPs (r2 < 0.06). Similarly, 
SNP rs6933669, recently reported as associated with age-at-menarche30, is uncorrelated with these 
five signals (r2 < 0.02) and was not associated with breast cancer (P=0.1). Thus, although there 
is a known relationship between age-at-menarche and breast cancer risk, they do not appear to 
share candidate causal variants in this region. 
 
Our findings help address the question of the role of ER-alpha in establishing breast cancer. 
Notably, the candidate causal SNPs identified here all increase risks of both ER+ and ER- 
tumor-subtypes by varying degrees. ER-alpha is a ligand-activated TF that mediates the effect 
of estrogen through altering gene expression and the link between estrogen, ER-alpha and ER+ 
breast cancer are well documented, with adjuvant endocrine therapy considered standard 
treatment for ER+, early-stage breast cancer. Other studies have also reported 6q25 associations 
with ER- subtypes1,2,5 but the mechanisms by which ER- tumors develop are still debated. There is 
speculation that ER- tumors may arise from ER+ precursors by potentially reversible mechanisms 
and our findings may lend support to this hypothesis. However, several recent studies have 
indicated that most tumors in BRCA1 mutation-carriers arise from ER- luminal progenitor cells, 
thus estrogen may be working indirectly through paracrine regulation in the mammary epithelium, 
possibly stimulating the Notch or EGFR signalling pathways of adjacent ER+ cells31,32. Our 
analyses unexpectedly revealed that whilst signals 1-4 increased risks of all ER- tumor subtypes, 
the signal 5 candidate causal variant increased risks of ER- HER2+ breast cancer subtypes but not 
of triple-negative tumor development or of tumors in BRCA1 mutation carriers (Table 1). This 
further complicates present understanding and underlines the need for further studies to address this 
issue. 
 
Collectively, our evidence supports a hypothesis that ESR1 is the major target gene of the 
enhancer and silencer elements in which we have identified candidate causal variants. In addition 
to ESR1, we provide evidence that the regions overlapping signals 1, 2, 3 and 4 cooperatively 
regulate RMND1, raising the possibility that candidate causal SNPs act by altering both ESR1 and 
RMND1 expression. RMND1 (Required for Meiotic Nuclear Division 1; C6orf96) has not been well 
characterized but is reported to localize to mitochondria and be involved in mitochondrial 
translation33. We additionally identified enhancer activity and chromatin interactions with two 
other genes, C6orf211 and CCDC170, but the actions of the candidate causal SNPs on these 
genes remain unclear. C6orf211 encodes Armt1, a protein carboxyl methyltransferase that targets 
PCNA and differentially regulates cancer cell survival in response to DNA damage34. Nothing is 
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known about the function of CCDC170 (Coiled- Coil Domain-Containing protein 170) but 
recurrent ESR1-CCDC170 rearrangements have been characterized in an aggressive subset of 
ER+ breast cancers35. A recent study also showed higher CCDC170 expression correlated with 
ER negativity, highly proliferative features and worse clinical outcomes36. There are some data to 
suggest that these genes may cooperatively contribute to the increased proliferative capacity of ER+ 
tumors20 and it is tempting to speculate that these may be additional target genes for the 
candidate causal variants at a subset of the five signals identified here, and perhaps responsible for 
their differential phenotype associations. A greater understanding of these genes may also provide 
novel targets for breast cancer prevention or therapies. 
 
 
URLs.  
1000 Genomes Project, http://www.1000genomes.org/; BCAC, http:// 
ccge.medschl.cam.ac.uk/consortia/bcac/index.html; CIMBA, http://ccge.medschl.cam.ac.uk/ 
consortia/cimba/index.html; COGS, http://www.cogseu.org/; iCOGS, 
http://ccge.medschl.cam.ac.uk/research/consortia/ icogs/; SNAP 
https://www.broadinstitute.org/mpg/snap/; TCGA, (https://tcga-data.nci.nih.gov); CGHub, 
https://cghub.ucsc.edu/; eMAP, www.bios.unc.edu/~weisun/software/eMAP.  
 
Accession codes. The relevant SNP genotype data underpinning these analyses can be accessed by 
applying to the BCAC and CIMBA consortia (see URLs). 
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FIGURE LEGENDS 
Figure 1. Association results for all SNPs with six phenotypes. Phenotypes analyzed include; 
(a) ER+ breast cancer risk from the BCAC, (b) ER- breast cancer risk from the BCAC, (c) 
triple negative breast cancer risk; derived from the CIMBA BRCA1/ ER- meta- analysis, (d) 
HER2+ breast cancer risk from the BCAC, (e) mammographic dense area from the MODE and 
(f) tumor grade after adjustment for ER status from the BCAC. P-values for each SNP (from 
unconditional logistic regression) are shown plotted as the negative log of the P-value against 
relative position across the locus. A schematic of the gene structures is shown above a and d. The 
physical positions of signals 1-5 are shown as colored, numbered stripes. 
 
Figure 2. ER expression and allelic imbalance correlates with signal 1 SNPs. (a) Negative 
association between the signal 1 SNP rs2046210 and ER protein expression. Black dots represent 
ER expression from individual samples measured by immunohistochemistry/H-score. P-values 
were calculated using a Spearman rank correlation test. (b) Boxplot of ESR1 gene expression 
(log2 transformed) in breast tumor and adjacent normal samples. Boxes extend from the 25th to 
the 75th percentile, horizontal bars represent the median, whiskers indicate the full range of ESR1 
expression, and outliers are represented as circles. (c) Allelic imbalance of ESR1 by breast cancer 
risk genotypic status. Plots are classified according to the genotypes for the risk SNP loci 
(heterozygotes vs homozygotes). Black dots represent the average of major allele fractions of the 
marker SNPs across ESR1 for a TCGA breast cancer individual. Red lines and whiskers 
correspond to mean and ±1 standard deviation. For rs7740686/signal 1 and rs9397437/signal 2, 
Levene's Test (equality of variances) and, for rs851985/signal 3, two-tailed t-Test (equality of 
means) was used to calculate P-values. 
 
Figure 3. Chromatin interactions across the 6q25.1 risk region. (a) Signals 1-5 are numbered 
and shown as colored stripes. RMND1, C6orf211, CCDC170, and ESR1 gene structures are 
depicted with exons (vertical boxes) joined by introns (lines). Gene-enhancer predictions from 
PreSTIGE12, ChIP-seq binding profiles for H3K27ac13 and ENCODE RNAPII ChIA-PET 
interactions in MCF7s are shown. 3C anchor points (3C baits) and sequences interrogated (3C 
regions) are depicted as black boxes and grey shading. 3C interaction profiles in ER+ MCF7 and 
ER- Bre-80 breast cell lines for signals 1 and 2 (b), signals 3 and 4 (c), or signal 5 (d). 3C 
libraries were generated with EcoRI, with the anchor points set at the ESR1, RMND1/C6orf211 or 
CCDC170 promoter regions. Graphs represent three biological replicates. Error bars represent SD. 
 
Figure 4. Risk alleles reduce ESR1 and RMND1 promoter activity. Luciferase reporter 
assays following transient transfection of ER+ MCF7 breast cancer cell lines. Putative regulatory 
elements (PREs) containing the major SNP alleles were cloned downstream of target gene 
promoter-driven luciferase constructs (prom) for the creation of reference (Ref- PRE) constructs. 
Minor SNP alleles were engineered into the constructs and are designated by the rs ID of the 
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corresponding SNP. Haplotype denotes a construct that contains the minor alleles of both 
candidate SNPs within either signals 1 or 3. Error bars denote 95% confidence intervals from three 
independent experiments. P-values were determined by 2-way ANOVA followed by Dunnett’s 
multiple comparisons test (**P < 0.01, ***P < 0.001). 
 
Figure 5. GATA3 and CTCF binding in vivo. (a) ChIP-qPCR assays using GATA3 or CTCF 
antibody in ER+ BT474 breast cancer cell lines. A region within the second intron of ESR1 
served as a negative (Neg) control. Graphs represent two biological replicates. Error bars represent 
SD. (b) 3C followed by sequencing for the signal 4-PRE containing rs1361024 in heterozygous 
ER+ MCF7 breast cancer cells shows allele-specific chromatin looping. Chromatograms represent 
one of three independent 3C libraries generated and sequenced. 
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Table 1. The associations of each signal-representative SNP with tumor risk and mammographic density in the three contributing consortia. 
 
 
For each signal-representative SNP (the best associated genotyped SNP) Odds Ratios for minor/major allele and conditional Odds Ratios (OR; cOR) and 95% 
Confidence Intervals (CIs), Hazard Ratios (HRs; cHR), Beta-coefficients (β; cβ) and P-values (P-cond) are from models including the other 4 signal-representative 
SNPs. Representative cORs and CIs could not be generated from the meta-analysis. 
n/a - SNP was not included in conditional analysis since individual effect was not significant at p>10-4 
*mammographic dense area, was square-root transformed and adjusted for age, BMI, menopausal status, study and relevant principal components. 
  
BCAC ER-ve 
CIMBA CIMBA BRCA1
Position Alleles Frequency ER-ve      ER+ve BRCA1 mutations Mammographic dense area* 
Representative SNP
OR (95%CIs) P-trend OR (95%CIs) P-trend HR (95%CIs)  P-value Meta analysis P-value β (95%CIs) P-trend
cOR (95%CIs) P-cond cOR (95%CIs) P-cond cHR (95%CIs) P-cond P-cond cβ (95%CIs) P-cond
1 rs3757322 151942194 GT 0.33 1.17 (1.12-1.21) 1.00E-14 1.07 (1.04-1.09) 1.10E-07 1.15 (1.10-1.20) 3.78E-10 2.50E-23 0.12 (0.07-0.17) 1.82E-06
1.14 (1.10-1.19) 1.51E-09 1.06 (1.04-1.09) 1.02E-05 1.10 (1.06-1.14) 3.79E-07 7.59E-15 0.07 (0.01- 0.12) 0.017
2 rs9397437 151952332 AG 0.07 1.28 (1.19-1.37) 5.29E-12 1.15 (1.10-1.20) 1.26E-09 1.24 (1.15-1.33) 3.98E-08 6.79E-19 0.27 (0.18- 0.36) 2.36E-09
1.18 (1.11-1.26) 1.20E-05 1.12 (1.07-1.17) 3.56E-06 1.12 (1.05-1.19) 3.60E-04 3.29E-08 0.22 (0.12- 0.32) 1.66E-05
3 rs851984 152023191 AG 0.41 1.04 (1.01-1.08) 0.024 1.06 (1.03-1.08) 1.97E-06 1.05 (1.01-1.10) 0.015 9.14E-04 -0.03 (-0.07- 0.02) 0.29
n/a 1.07 (1.05-1.10) 1.09E-08 1.07(1.03-1.10) 3.60E-04 3.12E-05 0.01 (-0.04- 0.06) 0.83
4 rs9918437 152072718 TG 0.07 1.18 (1.11-1.27) 6.20E-07 1.08 (1.04-1.13) 1.04E-04 1.17 (1.08-1.26) 1.30E-04 1.48E-10 0.03 (-0.05- 0.12) 0.45
1.13 (1.06-1.20) 4.46E-04 n/a 1.10 (1.04-1.17) 0.0015 2.61E-06 0.03 (-0.06- 0.12) 0.46
5 rs2747652 152437016 CT 0.54 1.12 (1.08-1.16) 1.83E-09 1.05 (1.03-1.08) 9.49E-06 1.00 (0.96-1.04) 0.95 1.44E-05 -0.02 (-0.07- 0.03) 0.39
1.12 (1.08-1.16) 2.32E-09 1.05 (1.03-1.08) 6.60E-06 1.00 (0.97-1.04) 0.86 5.97E-05 -0.02 (-0.07- 0.03) 0.45
BCAC
SIGNAL
MODE 
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Table 2. The association of each signal-representative SNP with the main tumor subtype combinations and tumor-grade. 
 
 
 
TN-Triple Negative 
SIGNAL 1 2 3 4 5
Representative+SNP rs3757322 rs9397437 rs851984 rs9918437 rs2747652
N"cases OR"(95%"CI) P OR"(95%"CI) P OR"(95%"CI) P OR"(95%"CI) P OR"(95%"CI) P
ER#Positive#
IHC"classification
"""""ER+/"PR±"/"HER2= 10,834 1.07 (1.03-1.11) 3.93E-04 1.14 (1.07-1.21) 9.54E-05 1.03(0.92-1.06) 1.40E-01 1.10(1.03-1.16) 4.16E-03 1.04(1.00-1.07) 3.67E-02
"""""ER+/"PR±"/"HER2+ 1616 1.10 (1.02-1.19) 1.68E-02 1.25(1.09-1.43) 1.05E-03 1.05(0.98-1.13) 1.88E-01 1.05(0.92-1.21) 4.75E-01 1.07(0.99-1.15) 7.22E-02
++++++++Case9only+P 6.60E-01 1.80E-01 3.90E-01 8.40E-01 4.00E-01
Grade"classification
"""""Grade"1 5331 1.05(1.00-1.10) 4.04E=02 1.04(0.96-1.14) 3.17E=01 1.00(0.96-1.05) 8.79E=01 1.07(0.99-1.16) 7.54E=02 0.98(0.95-1.03) 5.30E=01
"""""Grade"2 11498 1.08(1.04-1.11) 8.77E006 1.16(1.09-1.23) 1.48E006 1.05(1.02-1.08) 3.51E=03 1.08(1.02-1.14) 6.57E=03 1.06(1.03-1.10) 7.91E005
"""""Grade"3 4702 1.06(1.01-1.11) 1.37E=02 1.17(1.08-1.28) 2.22E004 1.11(1.06-1.16) 6.30E006 1.16(1.07-1.26) 2.17E004 1.21(1.08-1.17) 6.11E007
++++++++Case9only+P 9.20E=01 2.00E=02 2.60E=04 6.00E=02 7.97E-06
ER#negative#
IHC"classification
""""""ER=/PR=/HER2="(TN) 2840 1.20(1.1201.28) 7.17E008 1.25(1.1101.40) 1.50E004 1.05(0.98=1.12) 1.40E=01 1.17(1.0401.32) 7.00E-03 1.08(1.01-1.15) 1.65E-02
""""""ER=/PR=/HER2+ 858 1.19(1.07-1.32) 8.80E004 1.25(1.0401.5) 1.55E002 1.00(0.91=1.11) 9.40E=01 1.18(0.9901.40) 6.80E002 1.24(1.1201.37) 2.41E005
++++++++Case9only+P 7.80E-01 4.20E-01 1.40E-01 9.20E-01 2.08E-02
""""""ER=/PR+/HER2= 268 1.17(0.97-1.40) 9.00E-02 1.14(0.83-1.58) 4.10E-01 1.30(1.10-1.55) 2.50E-03 1.14(0.82-1.56) 4.40E-01 1.10(0.92-1.31) 2.90E-01
++++++++++Case9only+Ps++vs+TN 8.00E-01 7.80E-01 3.00E-02 6.50E-01 8.30E-01
vs+ER9/PR9/HER2+ 6.40E-01 6.10E-01 3.00E-02 1.60E-01 3.70E-01
vsER+/PR+9/HER2+ 7.90E-01 7.60E-01  1.20E-01 9.90E-01 3.80E-01
Grade"classification
"""""Grade"1 218 1.23(1.00-1.5) 4.40E-02 1.35(0.96-1.91) 8.60E=02 0.87(0.71-1.07) 1.60E-01 0.87(0.6-1.26) 4.70E-01 1.01(0.84-1.23) 9.00E-01
"""""Grade"2 1204 1.14(1.05-1.24 2.88E-03 1.19(1.02-1.39) 2.63E-02 1.09(0.99-1.18) 5.30E-02 1.26(1.09-1.45) 1.79E-03 1.12(1.03-1.22) 5.93E-03
"""""Grade"3 3463 1.20(1.13-1.26) 6.10E-11 1.30(1.19-1.43) 1.88E-08 1.05(0.995-1.10) 7.49E-02 1.19(1.09-1.31) 1.24E-04 1.12(1.05-1.17) 4.36E-05
Grade+polytomous+adjusted 9.18E-01 6.42E-03 5.43E-04 2.96E-01 1.82E-05
for+ER,+constrained
Suptypes<with<
strongest<associaton
ER0negative High<grade High<grade ER0negative ER0/HER2+<<
and<high<grade
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Table 3. Remaining candidate causal variants within each independent signal after likelihood ratio testing, based on the exclusion phenotype 
shown at the top of each column. 
 
 
 
1 Grayed out SNPs are mentioned in the text but have been excluded from being causal candidates based on likelihood ratio. 
SIGNAL
Representative SNP
Exclusion phenotype
Lead SNP
Lead SNP position
A1/A2
Frequency
Unexcluded candidates1 rs75859313 1.52E+08 1.83E-15 0.96 rs9397437 1.52E+08 3.29E-08 0.73 rs851985 1.52E+08 9.65E-12 1.00 rs6904031 1.52E+08 1.66E-05 0.82 rs910416 1.52E+08 2.70E-12 0.99
Chromosome position, rs3734806 1.52E+08 6.25E-15 0.87 rs58343273 1.52E+08 3.11E-08 0.75 rs851984 1.52E+08 1.11E-11 1.00 rs1361024 1.52E+08 8.74E-06 0.99 6-152434275 1.52E+08 2.24E-12 0.99
P-cond, r2 with lead SNP rs3757322 1.52E+08 7.59E-15 0.88 rs60954078 1.52E+08 1.32E-08 0.75 rs851983 1.52E+08 1.43E-11 1.00 rs9918437 1.52E+08 2.61E-06 1.00 rs34133739 1.52E+08 2.28E-12 0.99
rs11155803 1.52E+08 3.67E-15 0.89 rs9383937 1.52E+08 3.12E-08 0.73 rs851982 1.52E+08 1.45E-11 1.00 rs66485058 1.52E+08 5.81E-12 0.99
rs11155804 1.52E+08 2.13E-16 0.89 rs12173570 1.52E+08 2.92E-10 1.00 rs2747652 1.52E+08 1.23E-12 1.00
rs11155805 1.52E+08 2.83E-15 0.99 rs17081533 1.52E+08 3.85E-10 1.00 rs11345553 1.52E+08 4.69E-11 0.97
rs7740686 1.52E+08 2.28E-15 0.90 rs3757318 1.52E+08 9.78E-05 0.45
rs2046210 1.52E+08 4.38E-17 1.00
rs7763637 1.52E+08 2.60E-15 0.90
rs6557160 1.52E+08 2.58E-15 0.90
rs6557161 1.52E+08 6.51E-16 0.96
rs6900157 1.52E+08 4.72E-16 0.96
Overall breast cancer (BCAC)
1 2 3 4 5
rs3757322 rs9397437 rs851984 rs9918437 rs2747652
Meta-analysis (BCAC ER- CIMBA) Meta-analysis( BCAC ER- CIMBA) Overall breast cancer (BCAC) Meta-analysis( BCAC ER- CIMBA)
151948366 151957714 152020390 152072718 152437016
rs2046210 rs12173570 rs851985 rs9918437 rs2747652
1.07 (1.05-1.09) 1.23E-12
A/G T/C C/A G/T T/C
0.35 0.10 0.41 0.07 0.54
 Condtional OR (95%CI)               
P-trend overall breast cancer 
risk in BCAC
1.07 (1.05-1.09) 3.09E-09 1.12 (1.08-1.15) 1.64E-10 1.08 (1.05-1.10) 9.65E-12 1.05 (1.01-1.09) 1.27E-02
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ONLINE METHODS 
Study populations and genotyping 
Epidemiological data were obtained from three separate consortia that had all conducted genotyping 
using the iCOGS array, a custom array comprising approximately 200,000 SNPs:-1) Data on overall 
breast cancer risk, tumor subtypes and grade came from fifty breast cancer case-control studies 
participating in the Breast Cancer Association Consortium (BCAC); these comprized 41 studies 
from populations of European ancestry and nine studies from populations of East Asian ancestry3. 
Details of the participating studies, genotyping calling and quality control (QC) are given 
elsewhere3. After quality control exclusions, we analysed data from 46,451 cases and 42,599 
controls of European ancestry and 6,269 cases and 6,624 controls of Asian ancestry. A further 23 
SNPs were directly genotyped in two case-control studies (CCHS and SEARCH). Estrogen receptor 
(ER) status of the primary tumor was available for 34,539 European and 4,972 Asian cases; of these 
the tumor was ER- for 7465 (22%) European and 1610 (32%) Asian cases3. 2) Data on BRCA1 
mutation carriers were obtained through the Consortium of Investigators of Modifiers of BRCA1/2 
(CIMBA). Eligibility is restricted to females 18 years or older with pathogenic mutations in BRCA1 
or BRCA2. The majority of the participants were sampled through cancer genetics clinics37, 
including some related participants. 51 studies from 25 countries contributed data on BRCA1 
mutation carriers who were genotyped using the iCOGS array38. After quality control of the 
phenotypes and genotypes, data were available on 15,252 BRCA1 mutation carriers of whom 7,797 
had been diagnosed with breast cancer, all of European ancestry. Analyses in BRCA1 mutation 
carriers assessed associations with breast cancer risk. 3) Mammographic density information was 
available for 7,025 women from ten studies in BCAC and, in addition, 1,621 women from the Mayo 
Mammographic Health Study (MMHS). All were additionally participants in the Markers of 
Density Consortium (MODE). Forty-six women were excluded due to missing BMI information, 
leaving 8,600 women with mammographic density information, relevant covariates and iCOGS 
genotyping (2,955 breast cancer cases and 5,645 controls). Study details are given in 
Supplementary Table 14 and in Lindstrom et al39. Mammographic density measurements were 
performed on digitized analogue mammographic films using the ‘Cumulus’ software40. This applies 
a thresholding technique to measure the total area of the breast and the absolute dense area (DA), 
from which the absolute non-dense area (NDA) and percent dense area (PD) are derived. DA and 
NDA were converted to cm2 according to the pixel size used in the digitisation. Readers blind to 
genotype, case status and risk factor data conducted all measures. For cases, mammograms prior to 
the diagnosis of breast cancer were used or, where not possible, those from the contralateral breast. 
 
SNP selection, genotyping and imputation 
We first defined a mapping interval of ~1Mb (Chromosome 6 positions 151,600,000-152,650,000; 
NCBI build 37 assembly). We catalogued 2,821 variants with a minor allele frequency (MAF) > 
2% using the 1000 genomes project (March 2010 Pilot version 60 CEU project data), of these, we 
selected 277 SNPs correlated with the three previously reported associated SNPs (rs20462101, 
rs37573182 and rs302031441) at r2 > 0.1, plus a set of 698 SNPs designed to tag all remaining SNPs 
with r2 > 0.9. 902 SNPs passed QC were included in this analysis. After completion of iCOGs 
genotyping, this initial set was supplemented with a further 23 SNPs selected from the October 
2010 (Build 37) release of the 1000 Genomes Project, to improve coverage. These were genotyped 
in two large BCAC (CCHS and SEARCH) studies comprising 12,273 cases and controls, using a 
FluidigmTM array according to manufacturer’s instructions. Using the above data, results for all the 
additional known common variants (MAF > 0.02 in Europeans) on the January 2012 release of the 
1000 Genomes Project were imputed using IMPUTE version 2.0. QC and imputation steps were 
carried out separately in the different consortia leading to slight differences in the numbers of SNPs 
with available data: In addition to the 902 successfully genotyped SNPs, genotypes at 2972 SNPs 
were imputed in BCAC and 2907 in CIMBA (imputation r2 score > 0.3 in each case). 3872 
genotyped or imputed SNPs were available for the BCAC ER-/CIMBA BRCA1 meta-analysis. 
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Statistical analysis 
Case-control analysis, logistic regression and retrospective cohort analyses 
For the case-control analysis in BCAC, per-allele odds ratios (OR) and standard errors were 
estimated for each SNP using logistic regression, separately for subjects of European and Asian 
ancestry and for each tested phenotype. Principal components were included as covariates as 
previously described21. The statistical significance of each SNP was derived using a Wald test. To 
evaluate evidence for multiple association signals, we performed conditional analyses, in which the 
association for each SNP was re-evaluated after including other associated SNPs in the model. 
SNPs with a P-value < 10-4 and MAF > 2% in the single SNP analysis were included in this 
analysis21. Haplotype-specific odds ratios and confidence limits were estimated using haplo.stats22. 
 
Associations between genotypes and breast cancer risk in BRCA1 mutation carriers in CIMBA were 
evaluated using a 1 df per allele trend-test (P-trend), based on modeling the retrospective likelihood 
of the observed genotypes conditional on breast cancer phenotypes42. To allow for the non-
independence among related individuals, an adjusted test statistic was used which took into account 
the correlation in genotypes21. Per allele Hazard Ratio (HR) estimates were obtained by maximizing 
the retrospective likelihood. All analyses were stratified by country of residence.  
 
Conditional analyses were performed to identify SNPs independently associated with each 
phenotype. To identify the most parsimonious model, all SNPs with marginal P-value < 10-4 were 
included in forward-selection regression analyses with a threshold for inclusion of P-value < 10-4, 
and including terms for principal components and study. Similarly, forward-selection Cox-
regression analysis was performed for BRCA1 carriers, stratified by country of residence, using the 
same P-value thresholds. This approach provides valid significance tests of the associations, 
although the estimates quantifying the association can be biased42,43. Parameter estimates for the 
most parsimonious model were obtained using the retrospective likelihood approach.  
 
Within MODE mammographic DA, NDA and PD were each square-root transformed to fit a 
normal distribution. For the ten MODE/BCAC studies, a linear regression assuming a multiplicative 
per-allele model adjusting for study, age at mammogram, BMI, menopausal status (pre- or post-) 
and the first six principal components was carried out for each trait and for each SNP. The MMHS 
participants were analysed separately in the same way, but without the principal components 
covariates, and the results were combined with those from BCAC using a standard inverse variance 
weighted fixed-effects meta-analysis. 
 
Expression analysis  
Expression quantitative trait locus (eQTL) analyses were conducted in 57 normal breast samples 
from the Genotype-Tissue Expression (GTEx) project44 and 135 adjacent normal breast samples 
from women of Caucasian origin in the Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) study45. For the METABRIC analyses, matched gene expression 
(Illumina HT-12 v3 microarray) and germline SNP data that was either genotyped (Affymetrix SNP 
6.0) or imputed (1000 Genomes Project, March 2012 data using IMPUTE version 2.0) were used. 
Correlations between the five signal-representative SNPs and expression levels of nearby genes 
(500 Kb upstream and downstream of the SNPs) were assessed using a linear regression model in 
which an additive effect on expression level was assumed for each copy of the rare allele. 
Calculations were carried out using the eMap library in R. 
 
Allele specific expression (ASE) analysis 
ASE analysis has been described previously11. Three SNPs for signal 1, two SNPs for signal 3 and a 
proxy SNP for signal 2 (r2 = 0.85) were on the Affymetrix SNP Array 6.0. TCGA genotype calls 
and corresponding confidence scores were retrieved using level 2 TCGA SNP array Birdseed data 
downloaded from TCGA portal. Genotyping data with a confidence score of equal to or above 0.1 
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were excluded. We selected 742 breast cancer samples with Caucasian ancestry. The corresponding 
RNA-sequencing BAM files and metadata are available from the Cancer Genomics Hub (CGHub). 
Marker SNPs, the exonic SNPs of the target genes, were extracted from dbSNP human Build 142 
(collectively ~800 SNPs for ESR1, RMND1, C6orf211 and CCDC170) and RNA-sequencing read 
counts on SNP sites for reference and alternative alleles were computed. Homozygote marker SNPs 
and those with low coverage (less than 15x) were excluded. Major allele fraction (µ) representing 
allelic imbalance for each marker SNP was computed and an average of allelic imbalances for each 
gene was calculated for individual tumor samples. Marker SNPs with extreme µ values (µ > 0.75) 
were not included in the analysis. Level 3 SNP array data were downloaded from TCGA portal and 
GISTIC version 2.0.16 was used to identify copy number variations (CNVs) for each sample. 
Samples with low or high CNV levels, as presented in the gene-based GISTIC module report, were 
excluded from the analysis of the corresponding gene. For each risk SNP, allelic imbalance for the 
target transcripts was compared between heterozygote (AB) and homozygote (AA and BB) 
samples. For a given risk SNP and target gene, we used Levene's Test, a more robust test than F-
Test, for equality of variances when the risk SNP was not in linkage disequilibrium with any of the 
marker SNPs on that gene (r2 < 0.5). Otherwise, a two-tailed t-Test was used for equality of 
means46. 
 
Estrogen receptor (ER) protein expression 
Normal breast samples derived from 150 postmenopausal donors (non-Hispanic, mean age 62 
years) and identified through the Susan G. Komen for the Cure® Tissue Bank at the IU Simon 
Cancer Center were used in this study47. DNA was extracted from the blood cells at the Indiana 
CTSI Specimen Storage Facility using an AutogenFlex Star instrument (Autogen) and the 
Flexigene AGF3000 blood kit for DNA extractions (Qiagen). SNP analysis was performed with 1 
ng DNA using TaqMan genotyping assays for rs2046210 (C_12034236_10), rs3757322 
(C_27475059_10), rs9397437 (C_11556300_10), rs851984 (C_2496819_10), rs9918437 
(C_29496189_10), rs2747652 (C_2823750_10) from Life Technologies, following the 
manufacturer’s protocol. ER was measured by immunohistochemical semi-quantitation using a anti-
ERα antibody (clone 6F11; dilution 1/40; Leica Microsystems) and quantified with (i) H-score 
consisting of the sum of the percent of tumor cells staining, multiplied by an ordinal value 
corresponding to the intensity level (0 = none, 1 = weak, 2 = moderate, and 3 = strong; 
Supplementary Fig. 2), and (ii) percent of positive cells. Correlations between the H scores and 
ER IHC values were calculated using Spearman’s rank correlation analysis. All P-values reported 
are two-sided, and values < 0.05 were considered statistically significant.  
 
Cell lines  
Breast cancer cell lines MCF7 (ER+; ATCC #HTB22), T47D (ER+; ATCC #HTB133), BT474 
(ER+; ATCC #HTB20) were grown in RPMI medium with 10% FCS and antibiotics. Normal breast 
epithelial cell lines MCF10A (ATCC #CRL 10317) and Bre-80 (provided as a gift from Roger 
Reddel, CMRI, Sydney) were grown in DMEM/F12 medium with 5% horse serum (HS), 10 mg/ml 
insulin, 0.5 mg/ml hydrocortisone, 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin and 
antibiotics. Cell lines were maintained under standard conditions routinely tested for Mycoplasma 
and short tandem repeat (STR) profiled. 
 
Chromatin conformation capture (3C)  
3C libraries were generated using EcoRI, HindIII or BglII as described previously15. 3C interactions 
were quantitated by real-time PCR (Q-PCR) using primers designed within restriction fragments 
(Supplementary Table 15). Q-PCR was performed on a RotorGene 6000 using MyTaq HS DNA 
polymerase (Bioline) with the addition of 5 mM of Syto9, annealing temperature of 66oC and 
extension of 30 sec. 3C analyses were performed in three independent 3C libraries from each cell 
line with each experiment quantified in duplicate. BAC clones (RP11-108N8, RP11-713G5, RP11-
450E24, RP11-55K19) covering the 6q25 region were used to create artificial libraries of ligation 
26	  
	  
products in order to normalize for PCR efficiency. Data were normalized to the signal from the 
BAC clone library and, between cell lines, by reference to a region at within GAPDH. All Q-PCR 
products were electrophoresed on 2% agarose gels, gel purified and sequenced to verify the 3C 
product.  
 
Electromobility shift assays (EMSAs) 
Gel shift assays were performed with ER+ MCF7 or ER- Bre80 nuclear lysates and biotinylated 
oligonucleotide duplexes (Supplementary Table 16). Nuclear lysates were prepared using the NE-
PER nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific) as per the 
manufacturer's instructions. Total protein concentrations in nuclear lysates were determined by 
Bradford's method. Duplexes were prepared by combining sense and antisense oligonucleotides in 
NEBuffer2 (New England Biolabs) and heat annealing at 80°C for 10 min and slow cooling to 25°C 
for 1 hour. Binding reactions were performed in binding buffer [10% (vol/vol) glycerol, 20 mM 
HEPES (pH 7.4), 1 mM DTT, protease inhibitor cocktail (Roche), 0.75 µg poly(dI:dC) (Sigma-
Aldrich)] with 7.5 µg of nuclear lysate. For competition assays, binding reactions were pre-
incubated with 1 pmol of competitor duplex (Supplementary Table 17) at 25°C for 10 min before 
the addition of 10 fmol of biotinylated oligo duplex and a further incubation at 25°C for 15 min. 
Reactions were separated on 10% (wt/vol) Tris-Borate-EDTA (TBE) polyacrylamide gels (Bio-
Rad) in TBE buffer at 160 V for 40 min. Duplex-bound complexes were transferred onto Zeta-
Probe positively-charged nylon membranes (Bio-Rad) by semi-dry transfer at 25 V for 20 min then 
cross-linked onto the membranes under 254 nm ultra-violet light for 10 min. Membranes were 
processed with the LightShift Chemiluminescent EMSA kit (Thermo Fisher Scientific) as per the 
manufacturer’s instructions. Chemiluminescent signals were visualized with the C-DiGit blot 
scanner (LI-COR). 
 
Plasmid construction and reporter Assays 
Promoter-driven luciferase reporter constructs were generated by the insertion of PCR amplified 
fragments containing ESR1A, ESR1B, C6orf211, RMND1 or CCDC170 promoters into the KpnI 
and MluI sites of pGL3-Basic. To assist cloning, AgeI and SbfI sites were inserted into the BamHI 
and SalI sites downstream of the luciferase gene. A 1496 bp signal 1-putative regulatory element 
(PRE) fragment, a 997 bp signal 2-PRE fragment, a 1566 bp signal 3-PRE fragment, a 1463 bp 
signal 4-PRE fragment, and a 1349 bp signal 5-PRE fragment were generated by PCR or gBlocks 
(Integrated DNA Technologies) and cloned into AgeI and SbfI sites of the modified pGL3-promoter 
constructs. The minor alleles of individual SNPs were introduced into the PRE sequences by 
overlap extension PCR or gBlocks. Sequencing of all constructs confirmed variant incorporation 
(AGRF). ER+ MCF7 and BT474 or ER- Bre-80 cells were transfected with equimolar amounts of 
luciferase reporter plasmids and 50 ng of pRLTK transfection control plasmid with Lipofectamine 
3000. The total amount of transfected DNA was kept constant at 600 ng for each construct by the 
addition of pUC19 as a carrier plasmid. Luciferase activity was measured 24 hr posttransfection by 
the Dual-Glo Luciferase Assay System. To correct for any differences in transfection efficiency or 
cell lysate preparation, Firefly luciferase activity was normalized to Renilla luciferase, and the 
activity of each construct was measured relative to the promoter alone construct, which had a 
defined activity of 1. Statistical significance was tested by log transforming the data and performing 
2-way ANOVA, followed by Dunnett’s multiple comparisons test in GraphPad Prism.  
 
Chromatin Immunoprecipitation (ChIP) 
ER+ MCF7 and BT474 breast cancer cell were cross-linked with 1% formaldehyde at 37oC for 10 
min, rinsed once with ice-cold PBS containing 5% BSA and once with PBS, and harvested in PBS 
containing 1X protease inhibitor cocktail (Roche). Harvested cells were centrifuged for 2 min at 
3000 rpm. Cell pellets were resuspended in 0.35 mL of lysis buffer (1% SDS, 10 mM EDTA, 50 
mM Tris-HCl, pH 8.1, 1X protease inhibitor cocktail) and sonicated 3 times for 15 sec at 70% duty 
cycle (Branson SLPt) followed by centrifugation at 13000 rpm for 15 min. Supernatants were 
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collected and diluted in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM 
Tris-HCl, pH 8.1). Two micrograms of antibody was prebound for 6 hours to protein G Dynabeads 
(Life Technologies) and then added to the diluted chromatin for overnight immunoprecipitation. 
The magnetic bead-chromatin complexes were collected and washed six times in RIPA buffer (50 
mM HEPES [pH 7.6], 1 mM EDTA, 0.7% Na deoxycholate, 1% NP-40, 0.5 M LiCl), then twice 
with TE buffer. To reverse the cross-linking, the magnetic bead complexes were incubated 
overnight at 65oC in elution buffer (1% SDS, 0.1 M NaHCO3). DNA fragments were purified 
using a QIAquick Spin Kit (Qiagen). For QPCR, 2.0 uL from a 100 uL immunoprecipitated 
chromatin extraction and 40 cycles of amplification were used. All PCR products were sequenced 
by Sanger sequencing (AGRF). Antibodies used were ant-CTCF (C-20;sc-15914), anti-GATA3 
(HG3-31;sc268) and control IgG (sc-2027). ChIP primers are listed in Supplementary Table 18. 
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